➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RASAGILINE MESYLATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Rasagiline Mesylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00104273 Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed Eisai Inc. Phase 2 2004-08-01 The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00104273 Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) Completed Teva Pharmaceutical Industries Phase 2 2004-08-01 The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
NCT00203034 Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations Completed Teva Pharmaceutical Industries Phase 3 2000-05-01 Study for patients currently using Levodopa/Carbidopa who will be assigned to receive either Rasagiline or Placebo
NCT00203060 Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa Completed Teva Neuroscience, Inc. Phase 3 1997-07-01 Study to look at the effectiveness, tolerability and safety of two doses of Study Medication in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rasagiline Mesylate

Condition Name

Condition Name for Rasagiline Mesylate
Intervention Trials
Parkinson's Disease 6
Multiple System Atrophy 1
Dementia 1
Alzheimer's Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rasagiline Mesylate
Intervention Trials
Parkinson Disease 7
Dyssomnias 1
Shy-Drager Syndrome 1
Multiple System Atrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rasagiline Mesylate

Trials by Country

Trials by Country for Rasagiline Mesylate
Location Trials
United States 48
Canada 6
South Africa 3
Germany 2
Israel 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rasagiline Mesylate
Location Trials
California 5
Illinois 4
New York 4
Pennsylvania 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rasagiline Mesylate

Clinical Trial Phase

Clinical Trial Phase for Rasagiline Mesylate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rasagiline Mesylate
Clinical Trial Phase Trials
Completed 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rasagiline Mesylate

Sponsor Name

Sponsor Name for Rasagiline Mesylate
Sponsor Trials
Teva Pharmaceutical Industries 8
Technische Universität Dresden 1
H. Lundbeck A/S 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rasagiline Mesylate
Sponsor Trials
Industry 11
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
Johnson and Johnson
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.